SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emcure Pharmaceuticals reduces Poviztra dose price to expand patient access

02 Apr 2026 Evaluate

Emcure Pharmaceuticals has reduced price of its weight management drug Poviztra (semaglutide injection) across India. The reduced price would be starting at Rs 3,999 per month (MRP inclusive of taxes) (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s semaglutide injection for obesity, the company aims to expand access and enable more patients to benefit from this proven therapy at the revised price. The price revision, effective April 03, 2026, will bring the innovator molecule, backed by robust clinical and real-world evidence, within the reach of a significantly larger patient base across the country - at a time when obesity and weight-related health conditions are emerging as one of India’s most pressing public health challenges.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1660.00 -31.45 (-1.86%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×